Avian influenza: Exploring all the avenues

Annals of Internal Medicine

Volumn 145, Issue 8, 2006, Pages 631-632

  Treanor, John J ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; AVIAN INFLUENZA VACCINE; IMMUNOSUPPRESSIVE AGENT; OSELTAMIVIR; POLYCLONAL ANTIBODY; SIALIDASE; SIALIDASE INHIBITOR;

AVIAN INFLUENZA; CLINICAL FEATURE; DISEASE COURSE; DISEASE TRANSMISSION; EDITORIAL; HEMAGGLUTINATION; HUMAN; INFLUENZA VIRUS A H5N1; MEDICAL LITERATURE; MORTALITY; PANDEMIC; PRIORITY JOURNAL; PROPHYLAXIS; PUBLIC HEALTH SERVICE; TREATMENT OUTCOME; VIRUS ISOLATION; INFLUENZA; NOTE; PASSIVE IMMUNIZATION; VIRUS PNEUMONIA;

HUMANS; IMMUNIZATION, PASSIVE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA, HUMAN; PNEUMONIA, VIRAL;

EID: 33750701801     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-145-8-200610170-00140     Document Type: Editorial

References (11)

1. Maines TR, Chen LM, Matsuoka Y, Chen H, Rowe T, Ortin J, et al. Lack of transmission of H5N1 avian-human reassortant influenza viruses in a ferret model. Proc Natl Acad Sci U S A. 2006;103:12121-6.
2. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med. 2006;354:1343-51.
3. Bresson JL, Perronne C, Launay O, Gerdil C, Saville M, Wood J, et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/ 1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet. 2006;367:1657-64.
4. Li KS, Guan Y, Wang J, Smith GJ, Xu KM, Duan L, et al. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature. 2004;430:209-13.
5. Yen HL, Monto AS, Webster RG, Govorkova EA. Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J Infect Dis. 2005;192:665-72.
6. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006;145:599-609.
7. Rodriguez WJ, Gruber WC, Welliver RC, Groothuis JR, Simoes EA, Meissner HC, et al. Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group. Pediatrics. 1997;99:454-61.
8. Katz JM, Lim W, Bridges CB, Rowe T, Hu-Primmer J, Lu X, et al. Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts. J Infect Dis. 1999;180:1763-70.
9. Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. Nat Rev Microbiol. 2004;2:695-703.
10. Ison MG, Gubareva LV, Atmar RL, Treanor J, Hayden FG. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J Infect Dis. 2006;193:760-4.
11. Beigel JH, Farrar J, Han AM, Hayden FG, Hyer R, de Jong MD, et al. Avian influenza A (H5N1) infection in humans. N Engl J Med. 2005;353:1374-85.